Product Description
Mechanisms of Action: CRTH2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Asthma|Rhinitis, Allergic|Rhinitis, Allergic, Seasonal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2009-017267-41 | P2 |
Completed |
Asthma |
2010-09-02 |
2022-03-13 |
Treatments |
|
| CQAV680A2201E1 | P2 |
Terminated |
Asthma |
2010-09-01 |
2019-03-19 |
Treatments |
|
| CQAV680A2204 | P2 |
Completed |
Rhinitis, Allergic |
2010-07-28 |
2019-03-19 |
Treatments |
|
| 2008-005168-15 | P2 |
Completed |
Asthma |
2009-10-07 |
2022-03-12 |
Treatments |
|
| CQAV680A2201 | P2 |
Completed |
Asthma |
2009-10-01 |
2019-03-18 |
Treatments |
|
| CQAV680A2202 | P2 |
Completed |
Rhinitis, Allergic, Seasonal |
2008-12-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|